Charles M. Beasley

Eli Lilly and Company, USA 0000-0001-8743-7691

Charles M. Beasley, Ph.D., spent an internship at the Department of Psychiatry, Yale University, and he completed his training in psychiatry at the University of Cincinnati in 1987. He immediately joined Eli Lilly and Company in the area of clinical development of psychiatric medications. He currently holds the position of Distinguished Lilly Scholar working in Global Patient Safety. He has worked extensively with fluoxetine, atomoxetine, olanzapine, and tadalafil. His areas of interest include psychotropic medication clinical trial design and placebo response. His primary interests in the area of drug safety include suicidal ideation and behavior, hepatic function, and effects on cardiac ventricular repolarization. During his 24 years in industry with Lilly (as of 2011), he has authored over 90 peer-reviewed publications. He invented eight patents of Lilly products. He has extensive experience interacting with multiple divisions of the FDA, European regulatory authorities, and Japanese regulatory authorities. He is a Member of AOA, the American Psychiatric Association, the American Society for Clinical Psychopharmacology, the American College of Psychiatrists, the American College of Neuropsychopharmacology, and the American Federation for Clinical Research. He is also a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom.

Biography Updated on 12 December 2011

Scholarly Contributions [Data Provided by scopus]

download